tocilizumab,rituximab
roche,biogen
['toci', 'ritux', 'tocilizumab', 'imab ']
goldman et al. rtx, tcz in ssc ild. 129 patients, 87 rtx, 32 tcz, 10 both. median changes in %fvc and %dlco pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. majority stable/improved #acr22 abstr#1520 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC